Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 247

1.

New drugs and emerging therapeutic targets in the endothelin signaling pathway and prospects for personalized precision medicine.

Davenport AP, Kuc RE, Southan C, Maguire JJ.

Physiol Res. 2018 Jun 27;67(Supplementum 1):S37-S54.

2.

International Union of Basic and Clinical Pharmacology CIII: Chemerin Receptors CMKLR1 (Chemerin1) and GPR1 (Chemerin2) Nomenclature, Pharmacology, and Function.

Kennedy AJ, Davenport AP.

Pharmacol Rev. 2018 Jan;70(1):174-196. doi: 10.1124/pr.116.013177. Epub 2017 Dec 26. Review.

3.

The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY.

Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S, Gray AJG, Bruce L, Alexander SPH, Anderton S, Bryant C, Davenport AP, Doerig C, Fabbro D, Levi-Schaffer F, Spedding M, Davies JA; NC-IUPHAR.

Nucleic Acids Res. 2018 Jan 4;46(D1):D1091-D1106. doi: 10.1093/nar/gkx1121.

4.

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: G protein-coupled receptors.

Alexander SP, Christopoulos A, Davenport AP, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators.

Br J Pharmacol. 2017 Dec;174 Suppl 1:S17-S129. doi: 10.1111/bph.13878.

5.

THE CONCISE GUIDE TO PHARMACOLOGY 2017/18: Overview.

Alexander SP, Kelly E, Marrion NV, Peters JA, Faccenda E, Harding SD, Pawson AJ, Sharman JL, Southan C, Buneman OP, Cidlowski JA, Christopoulos A, Davenport AP, Fabbro D, Spedding M, Striessnig J, Davies JA; CGTP Collaborators.

Br J Pharmacol. 2017 Dec;174 Suppl 1:S1-S16. doi: 10.1111/bph.13882.

6.

Pharmacological targeting of apelin impairs glioblastoma growth.

Harford-Wright E, Andre-Gregoire G, Jacobs KA, Treps L, Le Gonidec S, Leclair HM, Gonzalez-Diest S, Roux Q, Guillonneau F, Loussouarn D, Oliver L, Vallette FM, Foufelle F, Valet P, Davenport AP, Glen RC, Bidere N, Gavard J.

Brain. 2017 Nov 1;140(11):2939-2954. doi: 10.1093/brain/awx253.

7.

Symptomatic Epidermoid Cyst Presenting as a Paravaginal Mass.

Davenport AP, Zimmerman CW, Hill BJ, Davis J.

Female Pelvic Med Reconstr Surg. 2017 May/Jun;23(3):e12-e13. doi: 10.1097/SPV.0000000000000392.

PMID:
28441277
8.

Vascular Imaging With 18F-Fluorodeoxyglucose Positron Emission Tomography Is Influenced by Hypoxia.

Joshi FR, Manavaki R, Fryer TD, Figg NL, Sluimer JC, Aigbirhio FI, Davenport AP, Kirkpatrick PJ, Warburton EA, Rudd JH.

J Am Coll Cardiol. 2017 Apr 11;69(14):1873-1874. doi: 10.1016/j.jacc.2017.01.050. No abstract available.

9.

Detection of Atherosclerotic Inflammation by 68Ga-DOTATATE PET Compared to [18F]FDG PET Imaging.

Tarkin JM, Joshi FR, Evans NR, Chowdhury MM, Figg NL, Shah AV, Starks LT, Martin-Garrido A, Manavaki R, Yu E, Kuc RE, Grassi L, Kreuzhuber R, Kostadima MA, Frontini M, Kirkpatrick PJ, Coughlin PA, Gopalan D, Fryer TD, Buscombe JR, Groves AM, Ouwehand WH, Bennett MR, Warburton EA, Davenport AP, Rudd JH.

J Am Coll Cardiol. 2017 Apr 11;69(14):1774-1791. doi: 10.1016/j.jacc.2017.01.060.

10.

[Pyr1]Apelin-13(1-12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13.

Yang P, Kuc RE, Brame AL, Dyson A, Singer M, Glen RC, Cheriyan J, Wilkinson IB, Davenport AP, Maguire JJ.

Front Neurosci. 2017 Feb 28;11:92. doi: 10.3389/fnins.2017.00092. eCollection 2017.

11.

18F-Fluoride and 18F-Fluorodeoxyglucose Positron Emission Tomography After Transient Ischemic Attack or Minor Ischemic Stroke: Case-Control Study.

Vesey AT, Jenkins WS, Irkle A, Moss A, Sng G, Forsythe RO, Clark T, Roberts G, Fletcher A, Lucatelli C, Rudd JH, Davenport AP, Mills NL, Al-Shahi Salman R, Dennis M, Whiteley WN, van Beek EJ, Dweck MR, Newby DE.

Circ Cardiovasc Imaging. 2017 Mar;10(3). pii: e004976. doi: 10.1161/CIRCIMAGING.116.004976.

12.

Elabela/Toddler Is an Endogenous Agonist of the Apelin APJ Receptor in the Adult Cardiovascular System, and Exogenous Administration of the Peptide Compensates for the Downregulation of Its Expression in Pulmonary Arterial Hypertension.

Yang P, Read C, Kuc RE, Buonincontri G, Southwood M, Torella R, Upton PD, Crosby A, Sawiak SJ, Carpenter TA, Glen RC, Morrell NW, Maguire JJ, Davenport AP.

Circulation. 2017 Mar 21;135(12):1160-1173. doi: 10.1161/CIRCULATIONAHA.116.023218. Epub 2017 Jan 30.

13.

Smooth Muscle Endothelin B Receptors Regulate Blood Pressure but Not Vascular Function or Neointimal Remodeling.

Miller E, Czopek A, Duthie KM, Kirkby NS, van de Putte EE, Christen S, Kimmitt RA, Moorhouse R, Castellan RF, Kotelevtsev YV, Kuc RE, Davenport AP, Dhaun N, Webb DJ, Hadoke PW.

Hypertension. 2017 Feb;69(2):275-285. doi: 10.1161/HYPERTENSIONAHA.115.07031. Epub 2016 Dec 27.

14.

Chemerin Elicits Potent Constrictor Actions via Chemokine-Like Receptor 1 (CMKLR1), not G-Protein-Coupled Receptor 1 (GPR1), in Human and Rat Vasculature.

Kennedy AJ, Yang P, Read C, Kuc RE, Yang L, Taylor EJ, Taylor CW, Maguire JJ, Davenport AP.

J Am Heart Assoc. 2016 Oct 14;5(10). pii: e004421.

15.

Cardiac action of the first G protein biased small molecule apelin agonist.

Read C, Fitzpatrick CM, Yang P, Kuc RE, Maguire JJ, Glen RC, Foster RE, Davenport AP.

Biochem Pharmacol. 2016 Sep 15;116:63-72. doi: 10.1016/j.bcp.2016.07.018. Epub 2016 Jul 27.

16.

Endothelin.

Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ.

Pharmacol Rev. 2016 Apr;68(2):357-418. doi: 10.1124/pr.115.011833. Review.

17.

Endothelin ETA receptors predominate in chronic thromboembolic pulmonary hypertension.

Southwood M, MacKenzie Ross RV, Kuc RE, Hagan G, Sheares KK, Jenkins DP, Goddard M, Davenport AP, Pepke-Zaba J.

Life Sci. 2016 Aug 15;159:104-110. doi: 10.1016/j.lfs.2016.02.036. Epub 2016 Feb 10.

18.

The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors.

Alexander SP, Davenport AP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Davies JA; CGTP Collaborators.

Br J Pharmacol. 2015 Dec;172(24):5744-869. doi: 10.1111/bph.13348.

19.

The Concise Guide to PHARMACOLOGY 2015/16: Overview.

Alexander SP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Buneman OP, Catterall WA, Cidlowski JA, Davenport AP, Fabbro D, Fan G, McGrath JC, Spedding M, Davies JA; CGTP Collaborators.

Br J Pharmacol. 2015 Dec;172(24):5729-43. doi: 10.1111/bph.13347.

20.

The Prodomain-bound Form of Bone Morphogenetic Protein 10 Is Biologically Active on Endothelial Cells.

Jiang H, Salmon RM, Upton PD, Wei Z, Lawera A, Davenport AP, Morrell NW, Li W.

J Biol Chem. 2016 Feb 5;291(6):2954-66. doi: 10.1074/jbc.M115.683292. Epub 2015 Dec 2.

21.

The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.

Southan C, Sharman JL, Benson HE, Faccenda E, Pawson AJ, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Spedding M, Catterall WA, Fabbro D, Davies JA; NC-IUPHAR.

Nucleic Acids Res. 2016 Jan 4;44(D1):D1054-68. doi: 10.1093/nar/gkv1037. Epub 2015 Oct 12.

22.

Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography.

Irkle A, Vesey AT, Lewis DY, Skepper JN, Bird JL, Dweck MR, Joshi FR, Gallagher FA, Warburton EA, Bennett MR, Brindle KM, Newby DE, Rudd JH, Davenport AP.

Nat Commun. 2015 Jul 7;6:7495. doi: 10.1038/ncomms8495.

23.

Apelin, Elabela/Toddler, and biased agonists as novel therapeutic agents in the cardiovascular system.

Yang P, Maguire JJ, Davenport AP.

Trends Pharmacol Sci. 2015 Sep;36(9):560-7. doi: 10.1016/j.tips.2015.06.002. Epub 2015 Jul 1. Review.

24.

Endothelin receptors and their antagonists.

Maguire JJ, Davenport AP.

Semin Nephrol. 2015 Mar;35(2):125-36. doi: 10.1016/j.semnephrol.2015.02.002. Review.

25.

LGR5 Activates Noncanonical Wnt Signaling and Inhibits Aldosterone Production in the Human Adrenal.

Shaikh LH, Zhou J, Teo AE, Garg S, Neogi SG, Figg N, Yeo GS, Yu H, Maguire JJ, Zhao W, Bennett MR, Azizan EA, Davenport AP, McKenzie G, Brown MJ.

J Clin Endocrinol Metab. 2015 Jun;100(6):E836-44. doi: 10.1210/jc.2015-1734. Epub 2015 Apr 27.

26.

Design, characterization, and first-in-human study of the vascular actions of a novel biased apelin receptor agonist.

Brame AL, Maguire JJ, Yang P, Dyson A, Torella R, Cheriyan J, Singer M, Glen RC, Wilkinson IB, Davenport AP.

Hypertension. 2015 Apr;65(4):834-40. doi: 10.1161/HYPERTENSIONAHA.114.05099. Epub 2015 Feb 23.

27.

Endothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12.

Maguire JJ, Davenport AP.

Br J Pharmacol. 2014 Dec;171(24):5555-72. doi: 10.1111/bph.12874. Epub 2014 Nov 24. Review.

28.

In vivo mapping of vascular inflammation using the translocator protein tracer 18F-FEDAA1106.

Cuhlmann S, Gsell W, Van der Heiden K, Habib J, Tremoleda JL, Khalil M, Turkheimer F, Meens MJ, Kwak BR, Bird J, Davenport AP, Clark J, Haskard D, Krams R, Jones H, Evans PC.

Mol Imaging. 2014;13. doi: 10.2310/7290.2014.00014.

PMID:
24825602
29.

Changes in biomechanical properties of the coronary artery wall contribute to maintained contractile responses to endothelin-1 in atherosclerosis.

Ooi CY, Sutcliffe MP, Davenport AP, Maguire JJ.

Life Sci. 2014 Nov 24;118(2):424-9. doi: 10.1016/j.lfs.2014.03.027. Epub 2014 Apr 8.

30.

Characterization of [¹²⁵I]GLP-1(9-36), a novel radiolabeled analog of the major metabolite of glucagon-like peptide 1 to a receptor distinct from GLP1-R and function of the peptide in murine aorta.

Kuc RE, Maguire JJ, Siew K, Patel S, Derksen DR, Margaret Jackson V, O'Shaughnessey KM, Davenport AP.

Life Sci. 2014 May 2;102(2):134-8. doi: 10.1016/j.lfs.2014.03.011. Epub 2014 Mar 15.

31.

Modulation of endothelin receptors in the failing right ventricle of the heart and vasculature of the lung in human pulmonary arterial hypertension.

Kuc RE, Carlebur M, Maguire JJ, Yang P, Long L, Toshner M, Morrell NW, Davenport AP.

Life Sci. 2014 Nov 24;118(2):391-6. doi: 10.1016/j.lfs.2014.02.020. Epub 2014 Feb 26.

32.

The Concise Guide to PHARMACOLOGY 2013/14: overview.

Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, McGrath JC, Catterall WA, Spedding M, Peters JA, Harmar AJ; CGTP Collaborators, Abul-Hasn N, Anderson CM, Anderson CM, Araiksinen MS, Arita M, Arthofer E, Barker EL, Barratt C, Barnes NM, Bathgate R, Beart PM, Belelli D, Bennett AJ, Birdsall NJ, Boison D, Bonner TI, Brailsford L, Bröer S, Brown P, Calo G, Carter WG, Catterall WA, Chan SL, Chao MV, Chiang N, Christopoulos A, Chun JJ, Cidlowski J, Clapham DE, Cockcroft S, Connor MA, Cox HM, Cuthbert A, Dautzenberg FM, Davenport AP, Dawson PA, Dent G, Dijksterhuis JP, Dollery CT, Dolphin AC, Donowitz M, Dubocovich ML, Eiden L, Eidne K, Evans BA, Fabbro D, Fahlke C, Farndale R, Fitzgerald GA, Fong TM, Fowler CJ, Fry JR, Funk CD, Futerman AH, Ganapathy V, Gaisnier B, Gershengorn MA, Goldin A, Goldman ID, Gundlach AL, Hagenbuch B, Hales TG, Hammond JR, Hamon M, Hancox JC, Hauger RL, Hay DL, Hobbs AJ, Hollenberg MD, Holliday ND, Hoyer D, Hynes NA, Inui KI, Ishii S, Jacobson KA, Jarvis GE, Jarvis MF, Jensen R, Jones CE, Jones RL, Kaibuchi K, Kanai Y, Kennedy C, Kerr ID, Khan AA, Klienz MJ, Kukkonen JP, Lapoint JY, Leurs R, Lingueglia E, Lippiat J, Lolait SJ, Lummis SC, Lynch JW, MacEwan D, Maguire JJ, Marshall IL, May JM, McArdle CA, McGrath JC, Michel MC, Millar NS, Miller LJ, Mitolo V, Monk PN, Moore PK, Moorhouse AJ, Mouillac B, Murphy PM, Neubig RR, Neumaier J, Niesler B, Obaidat A, Offermanns S, Ohlstein E, Panaro MA, Parsons S, Pwrtwee RG, Petersen J, Pin JP, Poyner DR, Prigent S, Prossnitz ER, Pyne NJ, Pyne S, Quigley JG, Ramachandran R, Richelson EL, Roberts RE, Roskoski R, Ross RA, Roth M, Rudnick G, Ryan RM, Said SI, Schild L, Sanger GJ, Scholich K, Schousboe A, Schulte G, Schulz S, Serhan CN, Sexton PM, Sibley DR, Siegel JM, Singh G, Sitsapesan R, Smart TG, Smith DM, Soga T, Stahl A, Stewart G, Stoddart LA, Summers RJ, Thorens B, Thwaites DT, Toll L, Traynor JR, Usdin TB, Vandenberg RJ, Villalon C, Vore M, Waldman SA, Ward DT, Willars GB, Wonnacott SJ, Wright E, Ye RD, Yonezawa A, Zimmermann M.

Br J Pharmacol. 2013 Dec;170(8):1449-58. doi: 10.1111/bph.12444.

33.

The CCR5 chemokine receptor mediates vasoconstriction and stimulates intimal hyperplasia in human vessels in vitro.

Maguire JJ, Jones KL, Kuc RE, Clarke MC, Bennett MR, Davenport AP.

Cardiovasc Res. 2014 Mar 1;101(3):513-21. doi: 10.1093/cvr/cvt333. Epub 2013 Dec 9.

34.

The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands.

Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, Davenport AP, McGrath JC, Peters JA, Southan C, Spedding M, Yu W, Harmar AJ; NC-IUPHAR.

Nucleic Acids Res. 2014 Jan;42(Database issue):D1098-106. doi: 10.1093/nar/gkt1143. Epub 2013 Nov 14.

35.

No evidence for a local renin-angiotensin system in liver mitochondria.

Astin R, Bentham R, Djafarzadeh S, Horscroft JA, Kuc RE, Leung PS, Skipworth JR, Vicencio JM, Davenport AP, Murray AJ, Takala J, Jakob SM, Montgomery H, Szabadkai G.

Sci Rep. 2013;3:2467. doi: 10.1038/srep02467.

36.

Evolving pharmacology of orphan GPCRs: IUPHAR Commentary.

Davenport AP, Harmar AJ.

Br J Pharmacol. 2013 Oct;170(4):693-5. doi: 10.1111/bph.12339.

37.

Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension.

Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W, Shaikh LH, Brighton CA, Teo AE, Davenport AP, Dekkers T, Tops B, Küsters B, Ceral J, Yeo GS, Neogi SG, McFarlane I, Rosenfeld N, Marass F, Hadfield J, Margas W, Chaggar K, Solar M, Deinum J, Dolphin AC, Farooqi IS, Striessnig J, Nissen P, Brown MJ.

Nat Genet. 2013 Sep;45(9):1055-60. doi: 10.1038/ng.2716. Epub 2013 Aug 4.

PMID:
23913004
38.

International Union of Basic and Clinical Pharmacology. LXXXVIII. G protein-coupled receptor list: recommendations for new pairings with cognate ligands.

Davenport AP, Alexander SP, Sharman JL, Pawson AJ, Benson HE, Monaghan AE, Liew WC, Mpamhanga CP, Bonner TI, Neubig RR, Pin JP, Spedding M, Harmar AJ.

Pharmacol Rev. 2013 May 17;65(3):967-86. doi: 10.1124/pr.112.007179. Print 2013 Jul. Review.

39.

Screening β-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors.

Southern C, Cook JM, Neetoo-Isseljee Z, Taylor DL, Kettleborough CA, Merritt A, Bassoni DL, Raab WJ, Quinn E, Wehrman TS, Davenport AP, Brown AJ, Green A, Wigglesworth MJ, Rees S.

J Biomol Screen. 2013 Jun;18(5):599-609. doi: 10.1177/1087057113475480. Epub 2013 Feb 8.

PMID:
23396314
40.

Themed section: endothelin.

Davenport AP, Barton M.

Br J Pharmacol. 2013 Jan;168(2):279-82. doi: 10.1111/bph.12022.

41.

IUPHAR-DB: updated database content and new features.

Sharman JL, Benson HE, Pawson AJ, Lukito V, Mpamhanga CP, Bombail V, Davenport AP, Peters JA, Spedding M, Harmar AJ; NC-IUPHAR.

Nucleic Acids Res. 2013 Jan;41(Database issue):D1083-8. doi: 10.1093/nar/gks960. Epub 2012 Oct 18.

42.

The Twelfth International Conference on Endothelin (ET-12), Cambridge 2011.

Barton M, Davenport AP.

Life Sci. 2012 Oct 15;91(13-14):462-5. doi: 10.1016/j.lfs.2012.07.015. Epub 2012 Jul 26.

43.

Cellular localization of receptors using antibodies visualized by light and dual labeling confocal microscopy.

Davenport AP, Kuc RE.

Methods Mol Biol. 2012;897:239-60. doi: 10.1007/978-1-61779-909-9_12.

PMID:
22674169
44.

Dynamic in vivo imaging of receptors in small animals using positron emission tomography.

Johnström P, Fryer TD, Bird JL, Richards HK, Davenport AP.

Methods Mol Biol. 2012;897:221-37. doi: 10.1007/978-1-61779-909-9_11.

PMID:
22674168
45.

Quantitative phosphor imaging autoradiography of radioligands for positron emission tomography.

Johnström P, Bird JL, Davenport AP.

Methods Mol Biol. 2012;897:205-20. doi: 10.1007/978-1-61779-909-9_10.

PMID:
22674167
46.

Radioligand binding assays and their analysis.

Maguire JJ, Kuc RE, Davenport AP.

Methods Mol Biol. 2012;897:31-77. doi: 10.1007/978-1-61779-909-9_3.

PMID:
22674160
47.

Defining the affinity and receptor sub-type selectivity of four classes of endothelin antagonists in clinically relevant human cardiovascular tissues.

Maguire JJ, Kuc RE, Davenport AP.

Life Sci. 2012 Oct 15;91(13-14):681-6. doi: 10.1016/j.lfs.2012.05.008. Epub 2012 May 23.

48.

The dual endothelin converting enzyme/neutral endopeptidase inhibitor SLV-306 (daglutril), inhibits systemic conversion of big endothelin-1 in humans.

Seed A, Kuc RE, Maguire JJ, Hillier C, Johnston F, Essers H, de Voogd HJ, McMurray J, Davenport AP.

Life Sci. 2012 Oct 15;91(13-14):743-8. doi: 10.1016/j.lfs.2012.03.022. Epub 2012 Mar 28.

49.

Comparison of human ETA and ETB receptor signalling via G-protein and β-arrestin pathways.

Maguire JJ, Kuc RE, Pell VR, Green A, Brown M, Kumar S, Wehrman T, Quinn E, Davenport AP.

Life Sci. 2012 Oct 15;91(13-14):544-9. doi: 10.1016/j.lfs.2012.03.021. Epub 2012 Mar 27.

50.

Comparison of endothelin receptors in normal versus cirrhotic human liver and in the liver from endothelial cell-specific ETB knockout mice.

Ling L, Kuc RE, Maguire JJ, Davie NJ, Webb DJ, Gibbs P, Alexander GJ, Davenport AP.

Life Sci. 2012 Oct 15;91(13-14):716-22. doi: 10.1016/j.lfs.2012.02.003. Epub 2012 Feb 18.

Supplemental Content

Loading ...
Support Center